Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

221,311-221,340 of 319,975

filter-aware
33
The slide uses a two-row layout to contrast GEN1 and GEN2 therapies, each with a 'Next Step' callout.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
34
Uses a ridge plot (joyplot) to visualize distribution of PRAME expression across 7 cancer types.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
35
The slide uses a chevron-based process flow to represent a phased development roadmap.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
36
The left side uses a funnel diagram to represent the manufacturing process steps.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
37
The table uses a multi-step funnel approach to arrive at the final patient population count.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
38
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
39
The slide uses a four-column layout to summarize the therapeutic profile of the drug candidate.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
40
Includes histological images of tumor/stroma and a longitudinal bioluminescence imaging study in mice.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
41
The slide features a high-quality photograph of a scientist handling cryogenic materials, reinforcing the 'off-the-shelf' (frozen/stored) nature of the product.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
42
The slide outlines a manufacturing process for off-the-shelf cell therapy.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
43
The slide uses a bulleted list to define the therapeutic rationale and two line charts to provide empirical evidence.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Why Now1 hit
44
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Why Now1 hit
45
The slide uses a structural diagram to explain the three components of the molecule and a process diagram to show the biological interaction.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Why Now1 hit
46
Includes a schematic diagram of the bispecific molecule on the left.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
47
The chart shows a clear performance advantage for the blue line (TCER®) over the grey lines.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
48
The chart uses a broken axis to show early time points and late-stage tumor volume divergence.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
49
The slide uses a 3x4 grid of line charts to demonstrate the safety profile of the proprietary TCER format.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
50
The slide uses a horizontal arrow-based process flow to categorize programs by development stage (Clinical vs Preclinical).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
51
Includes ISH images, a prevalence table, and a dot plot comparing peptide density.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
52
Includes study design timeline, histology details, and comparative tumor volume charts (group averages vs individual mice).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
53
The slide illustrates the methodology for PK analysis (injection, sampling, quantification) and presents the resulting concentration-time curve.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
54
The slide uses a process flow diagram to illustrate the transition from dose escalation to expansion cohorts.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
55
The slide uses four dose-response curves to show cytotoxicity against different target copy numbers.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
56
The chart uses a broken x-axis between -29 and 0. The legend indicates four distinct treatment groups.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
57
The slide uses a log-linear plot to demonstrate drug clearance over time.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
58
The slide outlines a standard clinical trial progression from overview to dose escalation and expansion.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
59
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
60
The slide uses a visual metaphor of cell-to-cell interaction to illustrate the therapeutic mechanism.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
61
The funnel is represented as a series of concentric circles/segments.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
62
The chart is a dot plot showing quantitative target density (CpC) for two different peptide targets.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit